ProfileGDS5678 / 1419154_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 42% 41% 41% 42% 41% 38% 41% 41% 41% 72% 41% 42% 41% 40% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0094742
GSM967853U87-EV human glioblastoma xenograft - Control 22.9416941
GSM967854U87-EV human glioblastoma xenograft - Control 32.9467841
GSM967855U87-EV human glioblastoma xenograft - Control 42.9046742
GSM967856U87-EV human glioblastoma xenograft - Control 52.8983341
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9631138
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.998841
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9264241
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9227341
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.6096872
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9247941
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9252342
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.94941
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9164340